High Dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention: Prespecified Substudy of a Prospective Randomized Clinical Trial

High Dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention: Prespecified Substudy of a Prospective Randomized Clinical Trial

The secondary endpoint was in-hospital, 1- and 6-month renal function change, and a composite of all cause mortality, myocardial infarction, renal failure requiring dialysis, heart failure, and target vessel revascularization.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2013-04, Vol.111 (7), p.95B-96B
Hauptverfasser: Jo, Sang-Ho, Hahn, Joo-Yong, Lee, Sung Yun, Kim, Hyun-Sook, Kim, Hyun-Joong, Choi, Yu Jeong, Kim, Hak Jin, Choi, Young-Jin, Lee, Sahng, Ahn, Kyoung-Ju, Song, Young Bin, Choi, Jin-Ho, Choi, Seung-Hyuk, Lee, Sang Hoon, Gwon, Hyeon-Cheol
Format: Artikel
Sprache:eng
Schlagworte:
Cardiovascular
Heart attacks
Kidney diseases
Medical research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The secondary endpoint was in-hospital, 1- and 6-month renal function change, and a composite of all cause mortality, myocardial infarction, renal failure requiring dialysis, heart failure, and target vessel revascularization.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2013.01.242